1: Ohtsuki M, Okubo Y, Komine M, Imafuku S, Day RM, Chen P, Petric R, Maroli A, Nemoto O. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial. J Dermatol. 2017 Aug;44(8):873-884. doi: 10.1111/1346-8138.13829. Epub 2017 Apr 9. PubMed PMID: 28391657; PubMed Central PMCID: PMC5573969.
2: Reed M, Crosbie D. Apremilast in the treatment of psoriatic arthritis: a perspective review. Ther Adv Musculoskelet Dis. 2017 Feb;9(2):45-53. doi: 10.1177/1759720X16673786. Epub 2017 Jan 20. Review. PubMed PMID: 28255338; PubMed Central PMCID: PMC5315225.